Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Actinium Pharmaceuticals Inc
ATNMCurrent price
1.78 USD
+0.07 USD (+4.09%)
Last closed
1.72 USD
Company
www.actiniumpharma.com
ISIN
US00507W2061
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
Capitalization
61 997 256 USD
Yield for 12 month
-72.74 %
1Y
3Y
5Y
10Y
15Y
ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for people with relapsed and refractory acute myeloid leukemia for bone marrow transplant; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York. Address: 100 Park Avenue, New York, NY, United States, 10017
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.8 USDP/E ratio
–Dividend Yield
–Current Year
+81 000 USD
Last Year
+1 030 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-709 000 USD
Last Year
+331 000 USD
Current Quarter
-189 000 USD
Last Quarter
-216 000 USD
Key Figures ATNM
1 year
3 years
5 years
10 years
EBITDA
-46 485 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-30.91 %
PEG Ratio
–
Return On Equity TTM
-87.96 %
Wall Street Target Price
5.8 USD
Revenue TTM
81 000 USD
Book Value
1.44 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
1 030 000 USD
Earnings per share
-1.51 USD
Diluted Eps TTM
-1.51 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ATNM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATNM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:30
Payout Ratio
–
Last Split Date
11.08.2020
Dividend Date
11.08.2020
Stock Valuation ATNM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
6.8399
Enterprise Value Revenue
1726.0705
Price Sales TTM
765.3982
Enterprise Value EBITDA
-3.6241
Price Book MRQ
1.4143
Financials ATNM
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ATNM
For 52 weeks
1.33 USD
10.24 USD
50 Day MA
5.21 USD
Shares Short Prior Month
2 145 250
200 Day MA
6.41 USD
Short Ratio
1.38
Shares Short
2 134 139
Short Percent
6.85 %
BeatStart